Key result
Higher glycaemic variability, measured by mean amplitude of glycemic excursion, significantly increased the risk of adverse cardiovascular events in patients with acute coronary syndrome (RR 1.76).
Why the study?
The relationship between different glycaemic variability indexes and adverse cardiovascular outcomes is not well understood.
Does higher glycaemic variability increase the risk of adverse cardiovascular events in patients with acute coronary syndrome?
Meta-Analysis (n=3,709)
Does higher glycaemic variability increase the risk of adverse cardiovascular events in patients with acute coronary syndrome?
Higher glycaemic variability is significantly associated with an increased risk of adverse cardiovascular events in patients with acute coronary syndrome.
Supports glycaemic variability monitoring in acute coronary syndrome; confirms adverse event risk and extends evidence on variability metrics.
Objective The relationship between different glycaemic variability (GV) indexes and adverse cardiovascular outcomes is not well understood. This study aims to determine whether GV is related to the occurrence of adverse cardiovascular events in patients with acute coronary syndrome (ACS). Methods PubMed, EMBASE, and Web of Science were comprehensively searched from the establishment of databases to 29 June 2022. The relationship between two important GV indexes, including the mean amplitude of glycemic excursion (MAGE) and standard deviation (SD), and the adverse cardiovascular events in ACS patients were evaluated, respectively. Results A total of 11 studies with 3709 ACS patients were included. Pooled results showed that patients with higher GV had significantly increased risk of adverse cardiovascular events, including MAGE (relative risk [RR] = 1.76, 95% CI: 1.40 to 2.22, p < 0.001, I 2 = 25%) and SD (RR = 2.14, 95% CI: 1.73 to 2.66, p < 0.001, I 2 = 0%). Conclusions Increased GV is related to the poor prognosis in patients with ACS. Additionally, more well-designed studies comparing different indicators of GV with adverse cardiovascular events in ACS patients are still warranted.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted a meta-analysis in Acute coronary syndrome (n=3,709). Higher glycaemic variability vs. Lower glycaemic variability was evaluated on Adverse cardiovascular events (RR 1.76, 95% CI 1.40 to 2.22, p=< 0.001). Higher glycaemic variability, measured by mean amplitude of glycemic excursion, significantly increased the risk of adverse cardiovascular events in patients with acute coronary syndrome (RR 1.76).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: